Peregrine Capital Management LLC Buys Shares of 84,324 Structure Therapeutics Inc. Sponsored ADR $GPCR

Peregrine Capital Management LLC bought a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 84,324 shares of the company’s stock, valued at approximately $5,865,000. Peregrine Capital Management LLC owned approximately 0.14% of Structure Therapeutics as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of GPCR. Balyasny Asset Management L.P. acquired a new stake in shares of Structure Therapeutics in the 3rd quarter valued at $12,923,000. Orbimed Advisors LLC boosted its holdings in shares of Structure Therapeutics by 49.5% in the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock valued at $24,873,000 after purchasing an additional 397,272 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new stake in shares of Structure Therapeutics in the 3rd quarter valued at $10,440,000. Casdin Capital LLC boosted its holdings in shares of Structure Therapeutics by 26.9% in the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after purchasing an additional 330,000 shares in the last quarter. Finally, Capricorn Fund Managers Ltd acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at $17,568,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GPCR. JPMorgan Chase & Co. raised their price objective on Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday. Wolfe Research began coverage on Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. Finally, Guggenheim raised their price objective on Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.00.

Structure Therapeutics Stock Up 1.1%

NASDAQ GPCR opened at $47.02 on Friday. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $15.80 and a twelve month high of $94.90. The company has a market cap of $3.33 billion, a price-to-earnings ratio of -59.52 and a beta of -1.17. The business’s fifty day moving average is $56.10 and its 200 day moving average is $55.01.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). On average, research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.36 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.